comparemela.com
Home
Live Updates
Ziftomenib Granted Breakthrough Therapy Designation by FDA in R/R AML : comparemela.com
Ziftomenib Granted Breakthrough Therapy Designation by FDA in R/R AML
The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.
Related Keywords
United States ,
American ,
Troy Wilson ,
American Cancer Society ,
Drug Administration ,
Kura Oncology Inc ,
Breakthrough Therapy Designation ,
Kura Oncology ,
Therapy Designation ,
Orphan Drug Designation ,
Nutritional Impacts ,
comparemela.com © 2020. All Rights Reserved.